LTR Pharma Past Earnings Performance
Past criteria checks 0/6
LTR Pharma's earnings have been declining at an average annual rate of -67.4%, while the Pharmaceuticals industry saw earnings growing at 35.1% annually. Revenues have been growing at an average rate of 79.5% per year.
Key information
-67.4%
Earnings growth rate
-791.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 79.5% |
| Return on equity | -236.5% |
| Net Margin | -14,192.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How LTR Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -7 | 3 | 4 |
| 31 Mar 24 | 0 | -5 | 2 | 3 |
| 31 Dec 23 | 0 | -3 | 1 | 2 |
| 30 Sep 23 | 0 | -2 | 1 | 1 |
| 30 Jun 23 | 0 | -1 | 1 | 1 |
| 30 Jun 22 | 0 | -1 | 1 | 0 |
Quality Earnings: LTP is currently unprofitable.
Growing Profit Margin: LTP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LTP's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LTP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LTP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (26.6%).
Return on Equity
High ROE: LTP has a negative Return on Equity (-236.5%), as it is currently unprofitable.